We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aplidin

News List

Spanish Medicines Agency Authorizes Aplidin, APLICOV-PC Trial for COVID-19 americanpharmaceuticalreview
April 30, 2020
PharmaMar has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS).
PharmaMar Submits Trial of Aplidin for COVID-19 to Spanish Medicines Agency americanpharmaceuticalreview
April 07, 2020
PharmaMar has announced the APLICOV clinical trial protocol for Aplidin® (plitidepsin) was submitted to the Spanish Medicines and Healthcare Products Agency (AEMPS).
PharmaMar Reports Positive Results for Aplidin Against Coronavirus contractpharma
March 16, 2020
Therapeutic target of Aplidin (plitidepsin), which is EF1A, is key to the multiplication and spread of the virus.
PharmaMar Starts Quadruple Combination Study with Aplidin americanpharmaceuticalreview
August 10, 2017
PharmaMar announced the start of a multicenter quadruple combination clinical study with Aplidin (plitidepsina), along with other compounds for the treatment of multiple myeloma. The main objective of this study is to evaluate the recommended dose (RD),